[1]
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74-108.
[2]
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60(5): 277-300.
[3]
Parkin DM. International variation. Oncogene 2004; 23(38): 6329-40.
[4]
Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009; 18(6): 1688-94.
[5]
Hrasovec S, Glavac D. MicroRNAs as novel biomarkers in colorectal cancer. Front Genet 2012; 3: 180.
[6]
Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4(3): 143-59.
[7]
Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435(7043): 834-8.
[8]
Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008; 26(4): 462-9.
[9]
Lanza G, Ferracin M, Gafa R, et al. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer 2007; 6: 54.
[10]
Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299(4): 425-36.
[12]
Reid JF, Sokolova V, Zoni E, et al. miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. Mol Cancer Res 2012; 10(4): 504-15.
[13]
Valeri N, Braconi C, Gasparini P, et al. MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell 2014; 25(4): 469-83.
[14]
Li E, Ji P, Ouyang N, et al. Differential expression of miRNAs in colon cancer between African and Caucasian Americans: implications for cancer racial health disparities. Int J Oncol 2014; 45(2): 587-94.
[15]
Wu X, Li S, Xu X, et al. The potential value of miR-1 and miR-374b as biomarkers for colorectal cancer. Int J Clin Exp Pathol 2015; 8(3): 2840-51.
[16]
Wang J, Huang SK, Zhao M, et al. Identification of a circulating microRNA signature for colorectal cancer detection. PLoS One 2014; 9(4): e87451.
[17]
Paraskevopoulou MD, Georgakilas G, Kostoulas N, et al.
DIANAmicroT
web server v5.0: service integration into miRNA functional
analysis workflows. Nucleic Acids Res 2013; 41(Web Server issue):
W169-73. Epub 2013/05/18.
2013.
[18]
Tops BB, Normanno N, Kurth H, et al. Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. BMC Cancer 2015; 15: 26.
[19]
Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13(11): 2498-504.
[20]
Kruger J, Rehmsmeier M. RNA hybrid: microRNA target prediction easy, fast and flexible 2006.
[21]
Chen J, Huang XF. The signal pathways in azoxymethane-induced colon cancer and preventive implications. Cancer Biol Ther 2009; 8(14): 1313-7.
[22]
Zhu H, Dougherty U, Robinson V, et al. EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulators. Mol Cancer Res 2011; 9(7): 960-75.
[23]
Wu CT, Lin WY, Chang YH, Lin PY, Chen WC, Chen MF. DNMT1-dependent suppression of microRNA424 regulates tumor progression in human bladder cancer. Oncotarget 2015; 6(27): 24119-31.
[24]
Oneyama C, Kito Y, Asai R, et al. MiR-424/503-mediated Rictor upregulation promotes tumor progression. PLoS One 2013; 8(11): e80300.
[25]
XY Xu, WJ Yan, WM Jiang, et al. MiR-424-5p promotes cell invasion and migration by targeting CYLD in human pancreatic cancer. Int J Clin Exp Med 2016; 9(3): 5960-8.
[26]
Li D, Xia L, Chen M, et al. miR-133b, a particular member of myomiRs, coming into playing its unique pathological role in human cancer. Oncotarget 2017; 8(30): 50193-208.
[27]
Chamorro-Jorganes A, Araldi E, Penalva LO, Sandhu D, Fernandez-Hernando C, Suarez Y. MicroRNA-16 and microRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1. Arterioscler Thromb Vasc Biol 2011; 31(11): 2595-606.
[28]
Chen B, Duan L, Yin G, Tan J, Jiang X. Simultaneously expressed miR-424 and miR-381 synergistically suppress the proliferation and survival of renal cancer cells-Cdc2 activity is up-regulated by targeting WEE1. Clinics (São Paulo) 2013; 68(6): 825-33.
[29]
Wu J, Ji X, Zhu L, et al. Up-regulation of microRNA-1290 impairs cytokinesis and affects the reprogramming of colon cancer cells. Cancer Lett 2013; 329(2): 155-63.
[30]
Ma Q, Wang Y, Zhang H, Wang F. MiR-1290 contributes to colorectal cancer cell proliferation by targeting INPP4B. Oncol Res 2017; 26(8): 1167-74.
[31]
Fodde R. The APC gene in colorectal cancer. Eur J Cancer 2002; 38(7): 867-71.
[32]
Fischer H, Stenling R, Rubio C, Lindblom A. Colorectal carcinogenesis is associated with stromal expression of COL11A1 and COL5A2. Carcinogenesis 2001; 22(6): 875-8.
[33]
Mitchell SM, Ross JP, Drew HR, et al. A panel of genes methylated with high frequency in colorectal cancer. BMC Cancer 2014; 14: 54.
[34]
Nosho K, Igarashi H, Nojima M, et al. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. Carcinogenesis 2014; 35(4): 776-83.
[35]
Wang Z, Ma B, Ji X, et al. MicroRNA-378-5p suppresses cell proliferation and induces apoptosis in colorectal cancer cells by targeting BRAF. Cancer Cell Int 2015; 15: 40.
[36]
Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7(8): 606-19.
[37]
Khaleghpour K, Li Y, Banville D, Yu Z, Shen SH. Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis 2004; 25(2): 241-8.
[38]
Liu X, Wang Y, Zhao J. MicroRNA-337 inhibits colorectal cancer progression by directly targeting KRAS and suppressing the AKT and ERK pathways. Oncol Rep 2017; 38(5): 3187-96.